Meetings
Conference abstracts
81 public abstracts from 2021 to 2026. Findings are the abstract’s own wording. Level 1 items, where ctDNA or MRD assigned treatment or surveillance, have a coral bar. Slide and poster links, when added, may require an ASCO or ESMO member login.
3 abstracts
- Level 2prognosticASCO Annual Meeting 2025
Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma.
Ansstas, George · Abstract 9571 · 197 patients; 1,718 plasma samples; retrospective real-world series; median 7 tests per patient over a median 24.7 months
Signatera (personalized tumor-informed 16-plex mPCR-NGS)
ctDNA positivity at any postoperative timepoint was associated with shorter RFS (HR 15.0, 95% CI 7.3-31.0, P<0.0001), particularly for distant or regional recurrence (HR 27.0). In a multivariate analysis (n=163), ctDNA positivity remained associated with RFS (HR 10.50, 95% CI 3.891-28.32, P<0.001). The abstract states ctDNA positivity influenced treatment-management changes in 28/38 (73.7%) of patients in whom that question was assessed.
- Level 2prognosticASCO Annual Meeting 2023
Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab.
Carlino, Matteo S. · Abstract LBA9515 · LBA · KEYNOTE-942 (mRNA-4157-P201) · 125 patients with evaluable baseline ctDNA; 110 (88%) ctDNA-negative at start of treatment
RaDaR (as stated in prior reports of this analysis; confirm brand is named in this abstract body if cited as such)
Baseline ctDNA-negativity was associated with longer RFS than positivity (event rate 20.9% [23/110] vs 80.0% [12/15]; HR 0.150, 95% CI 0.073-0.306). In the mRNA-4157/V940 plus pembrolizumab arm, RFS event rates were 10.4% (8/77) if negative vs 76.9% (10/13) if positive (HR 0.087). The pembrolizumab monotherapy comparison used only 2 ctDNA-positive patients.
- Level 3prognosticASCO Annual Meeting 2023
Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II/III melanoma.
Kollipara, Revathi · Abstract 9582 · 45 patients; assays designed for 42/45 (93%); 159 plasma samples; single-center real-world series
Signatera (bespoke mPCR-NGS)
ctDNA was detectable at one or more timepoints in 15/42 (36%), including 11/20 (55%) with stage III and 4/22 (18%) with stage II disease. Radiographic recurrence occurred in 7/42 patients, 6 of whom were ctDNA-positive. 26/27 (96%) patients with persistent ctDNA negativity remained clinically and radiographically progression-free. Twelve of 15 ctDNA-positive patients received adjuvant immunotherapy or treatment escalation after a positive result; 6 had sustained clearance.